This inventor holds 1 USPTO granted patent. Top assignee: Smithkline Beecham Corporation. Active years: 2012.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2012
Title: Innovator Spotlight: Donald Colin MacKenzie
Introduction: Donald Colin MacKenzie, based in Harlow, GB, is an accomplished inventor recognized for his significant contributions to the pharmaceutical field. With a focus on innovative medication compositions, he has made a lasting impact on medical science.
Latest Patents: MacKenzie holds a noteworthy patent related to a pharmaceutical composition. His invention comprises a thiazolidinedione, such as Compound (I), metformin hydrochloride, and a pharmaceutically acceptable carrier. This innovative formulation involves the unique dispersion of both the thiazolidinedione and metformin hydrochloride within their own respective carriers, enhancing the efficacy of the drug for medicinal use.
Career Highlights: He is currently associated with SmithKline Beecham Corporation, where he has contributed significantly to research and development initiatives. His work has helped pave the way for advancements in therapeutic solutions, particularly in diabetes management.
Collaborations: Throughout his career, MacKenzie has collaborated with notable colleagues including Karen Lewis and Nicola Jayne Lilliott. Together, they have worked towards the common goal of enhancing pharmaceutical formulations and improving patient outcomes.
Conclusion: Donald Colin MacKenzie’s innovative spirit and dedication to pharmaceutical research demonstrate the vital role inventors play in advancing medical science. His patent serves as a testament to the importance of innovation in creating effective therapeutic solutions for patients around the world.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile